Despite adherence to a rigorous methodology with precise preexpansion
calculations that culminate in the selection of an appropriate implant
, the predicted surface area gain after completion of tissue expansion
often falls short of the clinical requirements. Rather than then reso
rting to serial expansions, cutaneous overexpansion usually can be ach
ieved to reach the desired dimensions by overinflation of the implant
even well beyond the vendor's stated maximum volume. Over the past dec
ade in a series of 69 patients using 97 tissue expanders, some degree
of overexpansion was utilized in 53 implants (54.6 percent). No advers
e sequelae due to mechanical failure specifically attributable to this
hyperinflation occurred. Complications in the overinflation group (18
.9 percent) actually were significantly fewer than those observed in t
he underexpanded (41.9 percent) (p < 0.03) but were similar in classif
ication. Rather than any inherent superiority in the former group, thi
s observation probably more accurately reflects the fact that over-exp
ansion rarely could be done practically after a significant complicati
on. In any event, the proven safety of limited clinical overexpansion
allows a margin of error in the initial choice of implant volume and l
ater permits continued expansion if more tissue than originally antici
pated is needed.